Usp 825 training



Continue

The free loading of USP GC Appeal Updates RadioPharmaceuticals represent a unique class of medicines where compounds and other processing activities include the use of radionuclide generators, the preparation of commercially produced radiopharmaceutical kits, the dilution of FDA-approved multi-dose vials, the labeling of blood products with radionuclides. These activities take place at a time when the individual needs of patients and the safe handling of radioactive materials require a high level of care and well-defined standards that support these activities. The development of the USP General Chapter is a non-profit, science-driven organization that has an established process of convening independent experts to develop and maintain quality standards. This process is focused on public health, using modern science and technology, and draws on the experience of scientists and practitioners, providing opportunities for public input from stakeholders throughout the standard-setting process. USP develops standards for radiopharmaceuticals, including monographs for radioactive drugs and general chapters related to radioactivity and radiopharmaceuticals in general and some aspects for the combination of radiopharmaceuticals that emit positron. The USP Chemical Medicines Monograph 4 Expert Committee is responsible for the development of the general chapter of the zlt.825.gt. Review their work plan and past meetings. The chapter was published on June 1, 2019. Stay involved: Stakeholder engagement is an integral part of the standards-setting process. Stay involved and sign up to receive updates from USP. Return to radioactive articles for further updates and other information about USP's efforts to update and modernize monographs and general chapters of radioactive articles. Resources 1. What is radiopharmaceutical? Radiopharmaceutical (radiopharmaceutical preparation/radioactive drug) is defined as a ready-made form of dosage that contains a radioactive substance in connection with one or more ingredients and which is intended for diagnosis, stage of disease, monitoring of treatment or therapy. Radiopharmaceutical includes any set of non-radioactive reagents or radionuclide generator, which is designed for use in the preparation of any such substance. The terms radiopharmaceutical and radioactive drugs are used interchangeably. Because they contain radioactive materials, radiopharmaceuticals are subject to the control of the U.S. Nuclear Regulatory Commission (NRC) or government agency by entering into an agreement with the NRC. Also they are prescription drugs, radiopharmaceuticals fall under the control of the U.S. Food and Drug Administration (FDA). 2. Are radiopharmaceuticals classified as dangerous drugs by NIOSH because of radiation hazards? No. The National Institute for Occupational Health and Safety (NIOSH) dangerous drugs exclude radiopharmaceuticals, which are regulated by the Nuclear Regulatory Commission. 3. What is the goal? The goal is to provide uniform minimum standards for the preparation, connection, dosing and repackaging of sterile and non-sterile radiopharmaceuticals for humans and animals that take place as part of state-licensed activities (e.g. pharmacy and medicine). Describes facilities and engineering controls, staff training and qualifications, as well as procedural standards for the treatment of radiopharmaceuticals in nuclear pharmacies, nuclear medicine in hospitals and clinics, and other medical facilities using radiopharmaceuticals. For sterile radiopharmaceuticals, these standards balance the practice of aseptic treatment with radiation protection practices to describe appropriate strategies to ensure patient safety as well as ensure the safety of those performing these activities. 4. Why and how was it developed? It was developed in response to public comments, related to the 2015 revision of the white paper in 2016 by the Society for Nuclear Medicine and Molecular Imaging, as well as the USP's 2017 Stakeholder Workshop, which highlighted the unique characteristics of radiopharmaceuticals that make compliance with the 797-year-old difficult or impossible. It was developed by an expert panel of members of the USP Chemical Medicines 4 Expert Committee (which oversees radioactive drugs), the USP, FDA, Health Canada, nuclear pharmacists and nuclear medicine technologists. The draft document was published for public comment in July 2018. Public comments were received until November 2018. The final version, which addressed all public comments, was released on June 1, 2019 with an official date of December 1, 2020. 5. To whom and in what settings does it belong to? It applies to all persons who cook, compounds, dosing or repackaging radiopharmaceuticals. The individuals concerned will include authorized nuclear pharmacists (PP) and authorized pharmaceutical (AS) physicians, as well as those working under their supervision. This includes, but not limited to, student pharmacists, nuclear pharmacy technicians, nuclear medicine technologists and students and physicians residents and interns. It also applies to all practical installations in which radiopharmaceutical companies are prepared, aggravated, distributed or repackaged. Practical conditions include state-licensed nuclear pharmacies, federal nuclear pharmacies, but not limited to nuclear medicine departments in hospitals and clinics, nuclear cardiology clinics and others клиниками, которые занимаются радиофармацевтическими препаратами. 6. Являются ли радиофармацевтические препараты, соединенные 503B-установками или условно изготовленны в зарегистрированных FDA фармацевтических учреждениях, активными фармацевтическими ингредиентами (API)? Нет. Термин API относится к</825> </825> </825> </825> </825> </797> </797> </825> </825> </825> </825> </825> </825> </825> substance (pure chemical), usually in powder or liquid form, which is intended for use in the compound. The API differs from the finished dosage forms. 7. How do you know what the requirements are compared to the recommendations of the zlt;825?gt;? Typically, requirements in the general chapter are conveyed by means of term must. Recommendations are passed through the terms should and can. What does the official date mean? The official USP date indicates the date by which affected users must meet the requirements of a particular standard. It is the responsibility of regulators such as the FDA, states, other government agencies, and accreditation/certification organizations to ensure compliance with these standards. USP plays no role in law enforcement. 10. Are temperatures expressed in the degrees Fahrenheit or Celsius? Unless otherwise stated, all temperatures in USP-NF are expressed in Degrees Celsius (see also General Notices 8.180 Temperature). 11. Have there been any changes between the PF44 (5) Sep-Oct 2018 offer and the official version as a result of public comments? Yes. Based on public comments, changes have been made to the company. For example, the requirements for the immediate use of drugs have been presented as a new section 3. Immediate use of sterile radiopharmaceutical techniques. Another example of the change is the period of retraining of media filling competence has been increased from 6 months to 12 months. Details of the changes made in connection with public comments can be found in the commentary. 12. Is the administration for patients in the area? No. 13. Is the splitting of kits (faction) allowed? Defines the standards that must be met when the kit is divided. In the case of the kit, the separation of the kit

is defined as the act of dividing the contents of the kit bottle and transferring the aliquots to other storage containers and subsequent radio communications. Section 11.2 states that cleavage kits can be used to meet a patient's needs. For example, the contents of the kit bottle can be restored with 0.9% injection of sodium chloride and aliquoted into other storage containers and subsequent radiolate. The individual should consider all possible interactions of kit components with these other containers (e.g., container walls, closures), as well as possible changes in stability (e.g. physical and chemical stability) that can affect radiolabeling outputs of performance parameters when identifying the so-commanable BUD. Cm. Table 7 for the conditions of preparation of sterile radiopharmaceuticals. 14. Why is it necessary? Have reports of patients' harm from mishandling миоками? В этой главе описаны соответствующие стандарты, которые обеспечивают разумную гарантию безопасности пациентов, а также обеспечивают разумную гарантию безопасности</825> </825> </825> </825> </825> </825> </825> </825> </825> </825> these activities. There have been published reports of patient harm form the wrong radiopharmaceutical. Patel et al reported 16 patients who developed hepatitis C virus infections from contaminated radiopharmaceuticals used in myocardial perfusion studies (Patel PR, et al. Hepatitis C Viral Infections from Contaminated RadioPharmaceuticals used in myocardial perfusion studies. Jama. 2006; 296(16):2005-2011.) Moore et al reported several patients who developed hepatitis C virus infections from improper treatment practices at a nuclear cardiology clinic (Moore AP, et al. Transmission of hepatitis C virus during Myocardial Perfusion Imaging at an outpatient clinic. Am J Cardiol. 2011:108;126-132.) 15. How do the requirements of the NRC and the terms of the RAM license meet? As stated in the Introduction, other rules (e.g. NRC) must be followed in addition to the standards of the lt.825 in . In other words, there is nothing in the NRC's supersedes rules and requirements for a RAM license. For example, section 2 states that, in accordance with the requirements for an operational memory license, persons must wear the body and, as necessary, dosimeters of the limbs (e.g. a ring worn on the finger) for long-term monitoring of radiation exposure to staff. Any dosimeter of limbs should be worn under the gloves and should not interfere with the proper fit of the gloves. As another example, section 5.7 states: Users of RAM must comply with the conditions specified in the approved application and RAM license rules, and the terms of the ram license may overshadow the environmental control requirements described in this section. For sterile radiopharmaceuticals, the process balances aseptic treatments with radiation protection practices to describe appropriate strategies that ensure patient safety and ensure the safety of those performing these activities. 16. Should students and interns test their fingers in gloves and test the media before sterile radiopharmaceuticals are trained after immediate use? Yes, section 4.1 states: Staff must prove competence, as applicable to their work, before performing radiopharmaceutical aseptic tasks that are not suitable for immediate use. Specifically, the media filling section states: Media-filling testing is necessary for all employees who prepare, connect, dosage and repackage sterile radiopharmaceuticals. Section 4.3 describes situations where students or visitors do not have to prove competence. If a student or student will prepare, aggravate, distribute or repackage sterile radiopharmaceuticals for immediate use (in the ISO 5 PEC class), then they must observe aseptic qualifications in section 4, including aseptic training techniques, glove-tip testing, and media fill testing. 17. Can radiopharmaceuticals be able to qgt; qgt; qgt; qgt; qgt; qgt; qgt; qgt; qgt; for immediate use if the employee fails the media to fill out the call? Yes, section 3 reads: Does not require staff to complete the aseptic qualification, detailed in section 4.1 (e.g., aseptic training technique with documentary evaluation, media fill call, glove tip of finger testing) , so that the employee can prepare radiopharmaceuticals for immediate use, regardless of the results of their media fill the call. Nevertheless, some regulators and accreditors expect documented competencies in the implementation of critical activities, so documentation on the preparation and evaluation of the effectiveness of radiopharmaceutical preparation for immediate use is recommended. Should the media fill proctors with specialized or additional training? Section 4.1 states that the call that the media is filling will be monitored by the designated person. The designated person is defined as: One or more persons appointed responsible and accountable for the work and operation of a radiopharmaceutical processing plant, as well as for the staff who prepare, aggravate, distribute and repackage radiopharmaceuticals. The appointee must receive appropriate training in the field of supervision. 19. If the problem of filling the media is in one institution, should it be repeated at every facility the employee works for? Section 4.1 states: Staff must prove competence, as applicable to their work, before performing radio-pharmacetic aseptic tasks that are not suitable for immediate use. These qualifications can be held on another site if all SOPs are identical to the applicable job function. Testing media-filling is one component of the qualification of the competence, does not decide if it should be repeated in each facility the employee works in. 20. Do I need to prepare Y-90 v-vial microspheres in ISO 5 if they are used after 1 hour of preparation? Yes, intravascular radioactive devices (e.g. radioactive microspheres for intravascular brachytherapy) are supplied as a sterile device and must be treated with appropriate aseptic treatment practices to maintain infertility before administration. Section 3 states: All components involved (e.g. Tc-99m sodium pertechnetate syringe or vial, final prepared radiopharmaceutical kit vial, bomb bottle) must be discarded within one hour of puncture or after use for one patient Depending on what is the first, so if the Y-90 microsphere is not used within 1 hour of the first puncture of the vial they should be discarded. If an object wants to prepare and use the Y-90 microsphere (or any radiopharmaceutical) in 1 hour, ISO 5 PEC in SRPA is not required. See table 7. 21. Is it necessary to split a unit dose by 2 doses of ISO 5 PEC? Yes. See section 3, which says: Cleavage dose of zlt;/825 a specific dose for administration of more than one patient) cannot be performed as an immediate use; When performed, the fission dose must be performed in the ISO Class 5 PEC either in the SRPA or in the ISO 8 class or in the better buffer area. 22. If the bull Tc-99m pertechnetate vial obtained for emergency use is used to prepare radiopharmaceuticals for immediate use, can it be saved for additional patient research? No, see section 3, which states: All components involved (e.g. Tc-99m per superintendent syringe or vial, final prepared radiopharmaceutical kit bottle, scattering vial) should be discarded within one hour of puncture or after use for one patient administration, depending on which in the first place. Thus, any residual content of all the vials used should be discarded after 1 hour, so it cannot be retained for additional patient research. (Bulk technetium is the widely used name of a container (a bottle or syringe) supplied from a nuclear pharmacy to a nuclear medicine department or clinic, For use in the preparation of radiopharmaceuticals for emergency or urgent use. If applied for immediate use, sodium pertehnet can only be used for one patient. So most facilities can only use bulk technetium as a single-dose container for immediate use for one patient. 23. What detergents are suitable for areas potentially contaminated with bodily fluids, such as blood? The specification of specific cleaning products goes beyond the scope of the zlt.825. Individual agencies should create internal SOPs to provide training and referral staff in relation to cleaning, disinfection and application of sporicidal agents. For more information, please contact a product labeling specialist, an industrial hygienist, an environmental OSHA.gov officer, or company for more information. 24, What should I wear when cleaning with a sporicidal agent? The specification of a particular SIS goes beyond the scope of the 825.825. Individual agencies should create internal SOPs to ensure and personnel guidance regarding the cleaning, disinfection and application of sporicidal agents as described in section 7. Cleaning and disinfection. For more information, please contact a product labeling specialist, an industrial hygienist, an environmental OSHA.gov officer, CDC.gov company. 25. Should the gloves be sterile? The use of sterile gloves depends on the activity that is carried out. When working in a SRPA or buffer room, section 4.5 requires a section 4.5. The gloves that should be put on, like wearing sterile gloves reduces the bio burden brought into the SRPA or buffer room. When performing immediate use of the drug, section 4.4 reads either don sterile gloves or don non-sterile disposable gloves and then disinfect the gloves with a sterile 70% IPA. Sterile gloves are not required for immediate use. 26. Should the gloves be more or under the sleeve of the dress? The gloves should be above the sleeve of the dress in section 4.5, which states: The gloves should fully and tightly cover the ends of the cuff dress so that the skin on the wrists and upper hands is completely shrouded. Users should be reminded that the person performing the task is considered to be the highest source of potential particle shedding, which can lead to microbial contamination. 27. . Is the smoke hood or vent hood the same as is ITO 5 PEC? As stated in the PEC Glossary: A device or zone that provides iso Class 5 air quality to the environment for sterile treatment. Table 1 determines that ISO 5-class air particles should be less than 3,520 particles/m3 for the number of particles ≥0.5 microns measured in dynamic operating conditions using the High-Eating Particle Filter (HEPA). In contrast, the smoke hood does not contain the HEPA filter and exhausts volatile chemicals or radioactivity from the room to protect the operator, but does not protect sterile radiopharmaceuticals from bacterial or fungal contamination. Sometimes a smoke hood requires a RAM license, but it cannot be considered as a PEC for sterile drugs. 28. Is it possible to convert the smoke hood into ISO-5 PEC? No, because the standard equipment to qualify for the ISO 5 PEC is specialized and cannot be added to the installed smoke hood installation. 29. Is it possible to use the area used for food radio bleaching for immediate use of red cell markings or other sterile radiopharmaceuticals at the first cleaning? Yes, if the area is only used for one action during the entire processing time, then is cleaned before it is used for another action. Section 3 Immediate use of sterile radiopharmaceuticals states: The area of sterile preparation and/or dosing should be functionally separated from the non-sterile compound area (e.g. food protein) during use. Section 11.1 Of the link of non-sterile radiopharmaceutical activity states: Areas designated for non-sterile compounds must be cleaned and uncluttered and separated from areas designated for sterile radiopharmaceuticals. Section 10.4 The preparation of radio-bellied red blood cells for immediate use states: Dedicated blood processing space must be assigned in full blood radioleilation process. This area should be free from and not used for any other radiopharmaceutical or treatment until the completion of cleaning and disinfection. 30. Can SRPA be inside a hot lab? Yes, if the SRPA meets the requirements specified in Section 5 Services and Engineering Control for SRPA it may be a hot hot section According to the definition in the glossary, the hot laboratory is an unclassified radiopharmaceutical treatment area located in a hospital or clinical site that is suitable only for immediate radiopharmaceutical use if there is no ISO 5 PEC in the SRPA located within the area. Section 5.7 of the PSP states: All pressure monitoring devices must be checked for accuracy and performance at least once every 6 months. Does accuracy-tested and required performance mean rechecking or recalibration of the pressure monitoring device itself? What is a protocol if a device can only be re-certified if it is returned to the supplier (meaning it hasn't worked for some time)? Can this requirement be met by testing the device on a portable pressure unit? He does not describe how such testing should be carried out. Comparison with a calibrated/certified portable measuring device may be an acceptable option. The end user should discuss this with the cleanroom certificateer. 32. Is KK testing required for radiopharmaceutical systems prepared in accordance with the immediate use provisions? Section 3 is not fully prescriptive for all factors. In section 8. The purpose of BUD, there is a discussion of factors that should be considered when determining BUD, including maintaining radiochemical purity (which may require studying CK testing over time), but this will rarely be applied for immediate use. In section 9. The documentation it requires that records be retained for the final product of radiochemicals and other trials, if necessary, the results of drugs, drugs with minor abnormalities, and aggravated drugs. For some radiopharmaceutical kits, the package inserting instructions for training require KK verification, but for other radiopharmaceutical kits they do not. Section 10.2 Training with minor deviations includes a requirement for appropriate internal KK tests designed to test the radiochemical purity of the product for the entire BUD or supported by appropriate peer-reviewed publications for minor rejected. In addition to this, KK testing should be conducted as a professional standard of practice (e.g. see a document from SNMMI; the American College of Radiology and the American Pharmacists Association). 33. If a drug that has a biological distribution in the USP monograph is fractionally fractional according to the standard of a 96-hour compound (table 7) on what parameters should be checked before using a fractional product? It does not specify what quality control parameters should be met for complex radiopharmaceutical systems. For example, if a user splits with a traditionally manufactured freeze-dried medicinal product, section 8. The purpose of the BUD, says the person responsible for the manipulation assigns THE BUD based on established testing data, is either performed in-house or obtained from peer-reviewed literature. Section 8 also states that BUD is also dependent on the bud. quality and purity, including radiochemical purity, radionuclide purity and other applicable parameters specified in individual monographs or as clinically appropriate. In addition, section 11.2 states: The person responsible for this must take into account all possible interactions between the components of the kit and these other containers (e.g. container walls, closures), as well as possible changes in stability (e.g. physical stability, chemical stability) that may affect the radio whiteness of the yield or performance parameters in determining the appropriate BUD. Systematic KK testing is required to test the feasibility of a particular BUD. If the drug is aggravated by non-sterile components, Section 11.3 Sterile Compounds Use a non-sterile drug substance or components applied 34. Some visualization protocols require re-analysis of radiopharmaceutical systems in the SRPA or buffer room. How do I apply? It depends on the location of the calibrator dose. Section 7.6 Cleaning and disinfecting items from the Syringes patient care area that have been used in patient care should not be returned to a classified area (e.g. buffer or hallway) or SRPA for re-analysis or removal if the syringe is sealed inside an impenetrable container (e.g., sealed plastic bag) that is disinfected before entering the classified area. Users should consult with their epidemiology/infection control experts to properly apply the standards. 35. What are the cleaning and ALARA requirements for specific doses of pigs and vial shields that are sourced from an external source (e.g. a nuclear pharmacy, manufacturer) before they are additionally moved to specific areas (e.g. L-block) in a hot laboratory for further manipulation? The licensing obligations of radioactive materials include maintaining the impact on employees in accordance with THE principles of ALARA. Therefore, the practice of ALARA should always be taken into account when dealing with radioactive materials. If the hot laboratory does not have AN SRPA or PEC, there would be no restrictions or further requirements (such as cleaning) before moving the pigs and food bottled shields to areas in the hot laboratory where further radiopharmaceutical manipulation may take place. 36. What are the cleaning and ALARA requirements for the own dose of the pig facility unit, syringe shields and bottle shields that are maintained as part of the hot laboratory inventory (for example, never returned to a commercial source) before they are moved to specific areas (e.g. L-block) in a hot laboratory for further manipulation? The licensing obligations of radioactive materials include maintaining the impact on employees in accordance with THE principles of ALARA. That's why when you're working with materials should always take into account the practice of ALARA. If the hot lab does not have a SRPA or PEC, there would be no restrictions or further requirements (such as cleaning) before moving pigs or shields to any particular area in the hot lab. However, sections 7.6 and 10.4 of chapters indicate that cleaning expectations for equipment exposed to patient care areas and/or pathogens transmitted through the blood. Agencies should have their own procedures in place to account for these movements. 37. In an outpatient clinic not affiliated with the pharmacy, and therefore without the pharmacy director, who is responsible for radiopharmaceuticals? The authorized physician-user is responsible for radiopharmaceutical companies. Section 1. The introduction reads: The applicable persons are made up of authorized nuclear pharmacists (ANPs) and authorized user doctors (AU), as well as those working under their supervision. The broad purification and disinfection category in section 7.1 states that only 70 per cent of IPAs used in ISO-5 PEC are sterile; however, section 7.4 refers to the use of sterile 70% of IPAs. Sterile or non-sterile cleaning and disinfectant can be used, but if the disinfectant is not sterile, the process should be accompanied by a sterile 70% IPA. 39. If the area in the hospital is designated as RadioPharmaceutation, then does a pharmacy sterile unit license be required and a qualified pharmacist to be involved in aggravating these products? Depending on the state, radiopharmaceuty can be used synonymous with a nuclear pharmacy in relation to licensing by the State Pharmacy Board. In the department of nuclear medicine or clinic, the generic term hot laboratory is used to refer to the area for radiopharmaceuticals, but not pharmacy per se, which would require a separate license from the state pharmacy board. In any situation, the connection is performed under the supervision of an authorized user doctor or an authorized nuclear pharmacist. Does the set's radio connection include the packaging insertion? No, please refer to Glossary's USP definitions of radiopharmaceutical compounds, training and training with minor abnormalities. 41. Can a specific patient's dose be ready for immediate use with an emergency Tc-99m of vesodium pertehnet? Yes, it allows you to prepare (including a drug with minor abnormalities) and/or dosing, which is limited to use for one patient. Please refer to section 3. Immediate use of sterile radiopharmaceuticals for more details. 42. For radiopharmaceutical kits prepared in direct use, should radiochemical purity testing (RCP) be carried out? RCP testing can be performed at the care point prior to introduction, or by systematically checking the training procedures that the RCP provides. The term preparation includes not only the process to follow the manufacturer's recommendations, but also includes drugs with deviations from the manufacturer's recommendations. UsP Section 10. training is stated: The person responsible for the preparation of radiopharmaceuticals (s) Ensure that the final drug meets the quality and purity of the specifications throughout the designated BUD. This includes, in the case of preparation, radionuclide purity, radiochemical purity cleanliness chemical purity, as well as physical and chemical properties (mitalica added for accent). The FDA approval process is based on labeling instructions designed to maintain stability throughout use. Some radiopharmaceutical companies approved before 1990 do not have the rcP testing mentioned in their product labeling. The doctor or pharmacist is responsible for ensuring that the radiopharmaceutical is consistent with the quality and purity intended by the manufacturer and is responsible for the documentation as stated in section 9. Documentation that applies to the training category. In such situations, the USP monograph or other equivalent testing method used to ensure stability throughout THE BUD must be rigorous enough to ensure statistical validity of the results. 43. Is BUD limited to one (1) hour or less for immediate use? Yes, indicates that BUD for immediate use is one hour. Please refer to section 3. Immediate use of sterile radiopharmaceutical systems and information in Table 7. 44. Is a biosecurity cabinet required for xenons? The Biological Security Cabinet (BSC) is not suitable for xenon gas - rather, radioactive gases must be stored and treated in a chemical smoke hood or, as otherwise described in the facilities, special radioactive materials (RAM) licenses. 45. Is it necessary to observe and include a biosecurity cabinet or a glove box to contain segregated compounds? Deterrence Segregated Compound Area (C-SCA) is an object identified in USP dangerous drugs - Transfer in health settings and is not the object of design allowed in 46. Should the segregated radiopharmaceutical treatment area exert positive pressure in accordance with USP 825 and include a biosecurity cabinet or glove box? The segregated radiopharmaceutical treatment zone (SRPA) does not indicate pressure differentials; they must meet the conditions described in the license for radioactive materials of the facility. SRPA should include ISO 5 PEC (e.g. vertical laminar airflow of the work bench or Class II biological security cabinet) for radiopharmaceutical processing activities; The glove box is unacceptable. 47. Should the Hot Laboratory put negative pressure on the segregated radiopharmaceutical area and the corridor? There is no pressure differential for a hot laboratory, a segregated radiopharmaceutical treatment zone (SRPA) or other unclassified areas; pressure differentials must meet the conditions described in the facility's radioactive materials license. 48. Is a hallway or hallway required for a segregated radiopharmaceutical treatment area? No, the hallway is not required for segregated area of radiopharmaceutical treatment When entering the buffer zone, only a hallway (sometimes referred to as a clean room) is required. 49. For the immediate use of sterile radiopharmaceutical systems, it states: All components involved (e.g. Tc-99m perecann sodium syringe or vial, finally prepared radiopharmaceutical bottle, bomb bottle) must be discarded. 1 hour puncture or after use for one patient administration, depending on whether in the first place . Can the radioactive component be used to monitor the quality of the devices instead of discarded? Yes. Discarded radioactive material cannot be used for patients, but it can be used for generic use, such as instrument testing or as an external image source. 50. What cleaning procedures are needed for hot laboratories? Section 10.4 Of the Radio Scattering of Red Blood Cells for immediate use states: The cleaning and disinfection procedure by the appropriate agent (s) should be used to decontaminate the area and equipment before and after the radio communication is completed and all disposable components are discarded. Cleaning up for other activities performed in a hot lab goes beyond. This is a common area of infection control. Each agency must develop and follow appropriate infection control policies and procedures in accordance with professional practice guidelines and accreditation standards. 51. What kind of cleaning should be done on equipment used or exposed in the patient care area? Each agency should develop and follow appropriate infection control policies and procedures in accordance with professional practice guidelines and accreditation standards, subject to section 7.6 Cleaning and disinfection of items from the patient care area, which provides information on the cleaning and disinfection of items returned to the classified area (e.g. buffer or hallway) or SRPA. 52. Can heat-processed red blood cells, which are subsequently damaged, be considered a minor deviation, and can these TC-99m RBC be used in accordance with the direct use parameters set out in section 3? Yes, the thermal treatment of red blood cells is considered a minor deviation and can either be assigned a BUD or given as immediate use if all processes are done within one hour. 53. It is not clear whether nuclear medicine departments in hospitals should comply with USP standards, as they are not nuclear pharmacies. Introduction section states This chapter refers to all the practice of tuning where radiopharmaceuticals are prepared, aggravated, dispensed, or repackaged. Practice settings consist of state-licensed nuclear pharmacies, federal nuclear pharmacies and other medical facilities, including but not limited to: nuclear medicine departments in hospitals and clinics, nuclear cardiology clinics (fixed or mobile), and other specialized clinics. It goes on to say that this chapter applies to all individuals who prepare, compound, dispense, or repackage radiopharmaceuticals. The individuals involved will be nuclear pharmacists (PP) and authorized medical practitioners (AS), as well as those working under their supervision. This includes, but is not limited to, student pharmacists, nuclear pharmacy technicians, nuclear medicine technologists and students, as well as physician residents and interns. 54. Is it permissible to prepare kits using Ge-68/Ga-68 Ge-68/Ga-68 outside of the Class 5 ISO environment? As noted in Table 7, the Ge-68/Ga-68 generators are suitable for a secondary engineering control environment with a total number of particles in the air ISO 8. Any Ge-68/Ga-68 container generator or pipe assembly/connection must be made within iso 5 PEC. Additional product manipulations, including but not limited to removing the quality control sample, buffering the drug, etc., should be performed in the ISO 5 environment. 55. I work for a PET company that manufactures a variety of products under ANDAs, INDs and RDRC approvals. In addition, six months of PET drugs range from 10 minutes to more than 110 minutes. For short-lived products, one batch is used for one dose of the patient. For longer-lasting products, one batch is used for multiple doses of the patient. For these scenarios, could you explain the difference between partition punctures that occur during production and if they matter for purposes, especially with regard to the immediate use of provisions? The chapter states that its chapter does not apply to the production of approved radiopharmaceuticals (e.g. NDA, ANDA, BLA) in FDA-registered manufacturing facilities or the production of radiopharmaceuticals as investigative agents (e.g. IND, RDRC). In each of these scenarios, ... further processing and manipulation of the medicinal product after release falls under the scope of this chapter. Punctures made for KK testing are considered to be pre-sold sterling and do not apply to 56. For the category of immediate use, should the lab coat be cleaned dally or should disposable lab coats be used? In section 4.4, hand hygiene and garbing for immediate use of training, it states that ... Don a clean coat or dress that has not been exhibited on the patient area of patient care ... and another laboratory coat should be worn to care for the patient than the coat/dress used for radiopharmaceutical training. Each facility must develop policies and procedures for the use and wearing of laboratory coats or dresses in accordance with the provisions of this chapter. 57. Should a company that manufactures radiopharmaceuticals not intended for human or animal use follow the regulations? No. Introducing states, this chapter is designed to provide uniform minimum standards for the preparation, connection, dosing and repackaging of sterile and unsterile radiopharmaceuticals for humans and animals that occur within the framework of state-licensed activities. 58. Should the designated person be a pharmacy employee? No. The glossary defines the designated person as one or more persons appointed responsible and accountable for the operation and operation of the radiopharmaceutical processing plant, and for staff who prepare, exacerbate, distribute and repackage radiopharmaceutical companies. The institution is responsible for selecting a qualified company. to serve as a designated person. The chapter does not require a certain number of designated persons on the site or the discipline of the person (s) appointed. What is the expert group compared to the Expert Committee? The Panel of Experts is an advisory body established to provide additional expertise on specific comendic topics and to inform the Expert Committee on the development of standards. The panel of experts is developing recommendations for the Committee of Experts; The panel of experts does not vote by standards. What kind of KK testing is required for RP training, training with minor abnormalities and connections? Section 10 Preparation states: The person responsible for preparing the radiopharmaceutical (s) must ensure that the final drug meets the quality and purity of the specification of the entire designated BUD. Section 10.2 Preparation with minor deviations further states: This requires appropriate internal KK testing designed to test the radiochemical purity of the product for the entire BUD or supported by an appropriate peer-reviewed publication for minor deviations used. Section 11.2 Of the Sterile Connection states: In some cases, this may require systematic KK testing over time to verify the feasibility of a particular BUD. As for kits or fractionation of a conventionally manufactured vial, the chapter states: System testing of the KK is required to test the feasibility of a particular BUD. Section 11.3 Of the sterile compound using a non-sterile drug or component, it is stated that the sterilization and testing procedure described in the compound must be carried out. , radiochemical stability, solubility, or other parameters... in the definition of BUD. This may require testing to test the feasibility of a particular BUD. 61. Is it possible to divide the oral colloidal dose of Tc-99m sulfur into several syringes for multiple patients for non-sterile compounds (e.g. radio-culling products) without ISO 5 PEC? Stereric compounds do not require ISO 5 PEC. Section 3 The immediate use of sterile radiopharmaceutical techniques is only used for sterile radiopharmaceutical techniques. 62. Is it possible to divide into several syringes without CHP-5 PEC, if you use for one patient a sterile filtered Tc-99m sulphuric colloid) a unit of the dose of technetia (e.g. Tc-99m sestamibi, Tc-99m tetrofosmin, sterile filtered Tc-99m sulphur colloid) can be divided into several syringes without ISO 5 PEC if they are used for one patient and injected within an hour after separation Section 3 allows: Manipulations for any unit dose (e.g. dose reduction, needle change) or issuance for one patient (e.g. removal of dose) are permitted. It is necessary to enter within 1 hour after the first puncture of the container or exposure to any critical object (e.g., syringe tip, zlt;/85)gt; hub or needle) to the surrounding air, depending on what is first. All the components involved (e.g. ... bloated vial) should be discarded within 1 hour of puncture or after use for one patient administration, depending on what is the first. 63. Is an FDA-approved radiopharmaceutical record required for unapproved use? Section 9.1 states that if IFR is only required for training with minor abnormalities or connections. Approved and unapproved readings of radiopharmaceuticals refer to the procedure and use of the drug, which goes beyond the drug or the compound of the drug. MFR is required if the radiopharmaceutical is prepared with a slight deviation or is aggravated regardless of whether the indication is approved or not in the FDA assigning information. 64. What is a slight deviation and who defines it? defines a drug with a minor deviation as: The Act of preparation of a conditionally manufactured kit of the lt825gt; with conventionally manufactured radionuclide with volume and/or radioactivity and/or step-by-step deviations from the labeling recommended by manufacturers, while ensuring that the final preparation maintains appropriate radiochemical and radionuclide purity for the entire BUD. Examples of minor deviations include, but are not limited to, changes in the amount of activity or volume added to the vial, changes in turn-by-step operations mode (e.g., dilution of the Tc-99m solution after, not earlier, the addition to the vial, the use of a ventilation needle or filter), the use of alternative devices or equipment (e.g., a heating unit rather than a hot water bath), and the use of alternative electronic processing methods. This definition is adapted from the published FDA guidelines. 65. What counts as cosmetics? Cosmetics are defined in the Federal Law on Food, Medicines and Cosmetics as articles designed to rub, pour, sprinkle, or spray on, are introduced in, or otherwise applied to the human body... to cleanse, decorate, promote attractiveness, or change the appearance. FDC, No. 201 (i) It would be inappropriate to list all different types of cosmetics. Section 4.5 Hand hygiene and garbing for buffer zones and segregated radiopharmaceutical treatment specifically mention cosmetics. The USP states that clean-up should be carried out in the direction of the least clean areas. Does this mean that you would clear the PEC to the buffer zone or SRPA that contains the PEC? This link is specific to a specific area (i.e. PEC, buffer zone, ante room, SRPA). Cleaning should be done to prevent unintentional contamination of another newly cleaned area. However, the designated person (s) is responsible for making any decision based on the object. When to conduct and disinfection around the molybdenum-99/technetia-99m generator? All clean-up activities must be accompanied according to Table 5. The molybdenum99/technetium-99m generators fit into the Work of the zlt;/825-gt; outside the PEC or storing shelving and storage bins. Most molybdenum-99/technetia-99m generators have horizontal surfaces that are often used in the process of aseptic elusation. Use is more important than the use of storage space. Therefore, cleaning should be carried out on a daily basis using ALARA methods, such as extension tools that meet the conditions of the generator and use cleaning and disinfectant materials. SOPs should reflect the current practice of the facility. 68. Is it possible to prepare a blood-collection syringe containing an anticoagulant/estimated agent syringe (e.g. heparin/hetastarch) in a hot air laboratory to radiomark white blood cells? No, no, no, no, no, no, no, no, no, no BUD. White cell markings cannot be made on immediate use parameters, and the appropriate conditions for manipulation of all components are listed in Table 7. 69. When is coA required for radiopharmaceutical sterile compounds? When sterile radiopharmaceutical compound activity involves the use of bulk drug substance (which includes radionuclide, ligand, or other substances such as a precursor that becomes an active ingredient in the final radiopharmaceutical), Section 11.3 states that it must meet the standards of applicable USP or NF monographs if one exists, or be a component of the approved drug. Each mass drug must be produced by FDA-registered pharmaceutical institutions and accompanied by valid CoA procedures or equivalent testing procedures. 70. Why are sterile radioactive intravascular devices, such as the Y-90 microspheres, included in the USP? It was written to provide standards for the preparation, connection, dosing and repackaging of radiopharmaceuticals, including all sterile radioactive materials, which should maintain sterility through manipulation prior to administration. A sterile radioactive product can be a medicine or device and can be classified in several ways (e.g. radiopharmaceuticals, radioactive biologics, radioactive leaky sources and radioactive devices for intravascular brachytherapy). Since FDA-authoring often does not address the environment for preparation and distribution, or the corresponding Beyond Use Date (BUD) to be assigned after the manufacturer's vial has been punctured, USP has been written to set minimum qlt;825'gt; standards for these subsequent processing activities. In terms of manipulation, there may be no difference between the manipulation of the SIRSpheres Y-90 microsphere in the suspension (duration 24 hours after calibration) and the dosing of ioflupane I-123 (duration 7 hours after calibration), in-111 DTPA (duration 8 days after calibration), or any other other sterile injection or suspension (e.g. Tc-99m MAA suspension). Each of the products mentioned requires appropriate aseptic treatment and radiation safety to process the patient's dose from the bottle manufacturer, diluting if necessary to create a final form appropriate for parenteral administration. 71. What is a BUD for sterile intravascular devices? The post-calibration period of the manufacturer's product is not the same as BUD. BUD is a designated date and time after which a prepared, ready-to-patient radiopharmaceutical or radioactive product should not be administered as defined by the designated person (e.g., an authorized nuclear pharmacist authorized by the user). The designated BUD for the final dosage form for the patient (i.e. the patient's dose diluted if necessary, in a syringe or vial ready for introduction) is determined by the physical environment used in the processing of sterile radioactive material (see USP zlt;825, Table 7). If the sterile v-bottle is prepared or distributed in the ambient air, this treatment should follow section 3 associated with the immediate use of sterile radiopharmaceutical products, and will have a BUD of 1 hour from the time of the manufacturer's puncture vial. If a sterile intravascular device is prepared or distributed in ISO 5 PEC located in a SRPA or buffer room with an ante room, a longer BUD can be assigned, as described in table 7 chapters (i.e. 12 hours, 24 hours or 96 hours, depending on the specific requirements of the table). 72. If a unit dose is distributed or repackaged from sterile multidose radiopharmaceutical with preservative (e.g. Tl-201 tallide chloride, Ga-67 gallium citrate) in ISO 5 PEC in SRPA or buffer room with an ant room makes BUD on multi-dose should be adjusted after puncture? This dosed or overpackal dose should follow the BUD positions in Table 7. After the puncture of the multi-dose container, the manufacturer's shelf life no longer applies; a restless date must be applied. A multi-dose container with preservatives must be used for 28 days unless otherwise specified by the manufacturer-labeling (see Requirements for multi-dose containers, 73. Does USP require an analysis certificate for an FDA-approved product if you are prepared with minor abnormalities or connections? According to 9.1 Master Formulation Record, it states that MFR is necessary for training with minor deviations or connections; examples of data to be included are name, identity, strength, purity, quality and quantity of ingredients with proven documentation (e.g. CoA). While coA is an example of one type of proven documentation, prescribing information from an FDA-approved product is also a valid example. 74. If the external eleuent should be punctured to the elus, in what environment should it occur (e.g. external HCl, removal of volume from a normal salt bottle)? Puncture and adjustment of the volume of the eleuent (e.g., a conventional sael vial, external HCl) must take place in the ISO 5 PEC class before to eleth the generator. 75. Is the designated person obligated to subscribe to something similar to that of a specialist Object? Section 14 of THE KE AND KE QUALITY CONTROL states: The designated person must ensure that the site has formal, written quality control and KK programmes that establish the system: compliance with procedures, prevention and detection of errors and other quality issues, evaluation of complaints and adverse events, as well as appropriate investigations and corrective actions. SOPs should describe the roles, responsibilities and training of the personnel responsible for every aspect of the quality control program. The general quality control and KK programme should be reviewed at least once every 12 months by the designated person. The results of the review must be documented and appropriate remedial action should be taken if necessary. As described, the designated person must document the annual review of the quality assurance and quality control programme. This is the only section of the chapter that requires documentation from the designated person. Man.

xepuripo.pdf
mifav.pdf
vozulawinuvad.pdf